Immuno-Oncology | Specialty

Pembrolizumab Improves Survival in PD-L1-Positive NSCLC

December 20th 2015

Treatment with pembrolizumab reduced the risk of death by 29% compared with docetaxel for patients with PD-L1-positive non–small cell lung cancer.

Lenvatinib in Metastatic Renal Cell Carcinoma

December 19th 2015

PD-1 Inhibition in Metastatic Renal Cell Carcinoma

December 19th 2015

Perspectives on Sequencing in Metastatic RCC

December 19th 2015

Goals in Relapsed/Refractory Metastatic RCC

December 19th 2015

mTOR Inhibition for Poor-Risk RCC

December 19th 2015

Frontline Therapy Selection in Metastatic RCC

December 19th 2015

Frontline TKI Selection in Metastatic RCC

December 19th 2015

First-Line Considerations in Metastatic Renal Cell Carcinoma

December 19th 2015

T-VEC Approved in Europe for Unresectable Metastatic Melanoma

December 18th 2015

The European Commission has approved talimogene laherparepvec as a treatment for adult patients with unresectable stage IIIb, IIIc, and IVM1a melanoma that has not spread to the bone, brain, lung, or other viscera.

FDA Approves Two New Indications for Pembrolizumab in Advanced Melanoma

December 18th 2015

The FDA has expanded the approval for single-agent pembrolizumab to include the frontline treatment of patients with advanced melanoma regardless of BRAF status.

Urologists Adapt Treatment Paradigm to Incorporate Novel Agents in mCRPC

December 15th 2015

Raoul S. Concepcion, MD, FACS, discussed novel therapies for treating mCRPC and deciding which patients are appropriate candidates.

Dr. Petrylak on Atezolizumab in Bladder Cancer

December 15th 2015

Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center, discusses the anti–PD-L1 antibody atezolizumab in bladder cancer.

Dr. Omid Hamid on Vemurafenib and Atezolizumab in Melanoma

December 14th 2015

Omid Hamid, MD, Chief, Translational Research and Immunotherapy, Director, Melanoma Therapeutics, The Angeles Clinic, discusses a recent trial investigating the combination of vemurafenib and atezolizumab in melanoma in patients with previously untreated BRAF-positive unresectable or metastatic melanoma.

James Allison on Exciting Immunotherapy Advancements in Melanoma

December 14th 2015

James Allison, chair of Immunology at the University of Texas MD Anderson Cancer Center, discusses promising data regarding the use of immunotherapies in melanoma. Allison is particularly excited about a trial, presented at the Society of Melanoma Research Congress, which looked at the combination of PD-L1 inhibitors with a BRAF-targeted agent.

Pembrolizumab Continues to Show Promise in Breast Cancer

December 12th 2015

The PD-1 inhibitor pembrolizumab had an overall response rate of 12% in PD-L1–positive patients with ER-positive/HER2-negative advanced breast cancer.

Dr. Saeed Rafii on Atezolizumab/ Nab-paclitaxel in TNBC

December 11th 2015

Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute United Kingdom, discusses a study evaluating the safety and clinical activity of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (TNBC).

Atezolizumab/Nab-Paclitaxel Combo Shows High Response Rates in TNBC

December 10th 2015

Frontline treatment with the PD-L1 inhibitor atezolizumab combined with nab-paclitaxel showed a confirmed objective response rate of 66.7% in patients with metastatic triple-negative breast cancer.

Avelumab Effective in PD-L1-Positive Metastatic Breast Cancer

December 9th 2015

Treatment with the PD-L1 inhibitor avelumab demonstrated promising overall response rates for patients with PD-L1–positive metastatic breast cancer, particularly for those with triple-negative disease.

Dr. San Miguel on Pembrolizumab With Lenalidomide/ Dexamethasone in Multiple Myeloma

December 8th 2015

Jesus San Miguel, MD, PhD, professor of Hematology, medical director of the Clínica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain, discusses the Keynote-023 study, which examined pembrolizumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.